Hims & Hers Health (NYSE: HIMS) stock plummeted more than 18% in after-hours trading on Monday after the telehealth company
12 months ago
Shares of Hims & Hers Health (NYSE: HIMS) plunged 23% on Friday after the U.S. Food and Drug Administration (FDA)
Canaccord Genuity analyst Maria Ripps raised her price target for Hims & Hers Health (NYSE: HIMS) to $68.00, up from
NEW YORK – On Wednesday, Hims & Hers Health (NYSE: HIMS), the U.S. telehealth company, said it will sell compounded
1 year ago
